Browse drugs

…d OS of 13.4 months,38 39 leading to full FDA approval in 2024. Adagrasib has also shown modest activity in PDAC (ORR 33%, PFS 5.4 months…

… among the GLP-1RA group compared with the sulfonylureas group. GLP-1RA=glucagon-like peptide-1 receptor agonistsDiscussionIn this nati…

…ple with T2DM and established CVD to receive either the SGLT2i, empagliflozin, or placebo.5 To be eligible for this study, people had to meet…

…state health sector in which several novel cancer drugs such as osimertinib, alectinib and immunotherapy are not approved for use in advanc…

…de (25 936), empagliflozin (715 802), sitagliptin (493 563) and glipizide (832 295) ( online supplemental eTable 1, 5–8). Baseline charac…

… insulin requirements in patients with hyperglycemia prescribed prednisolone, with an aim to inform individualized insulin dosing.19 In this…

…ysiological environment of pregnancy and delivery. Opioids like fentanyl and sufentanil have proven to be reliable for providing quick p…

…ted the true neuroprotective effects of GLP-1 RAs compared with metformin. This underscores the potential superiority of GLP-1 RAs and hi…

…ently, however, many low income countries do not have access to tranexamic acid, and multiple agencies are working together to improve the manu…

…ltiple risk factors for cardiovascular disease, irrespective of metformin use.14–19Despite the demonstrated benefits of SGLT2i and GLP-1R…

…en of nausea and vomiting was reported in patients treated with ipilimumab. 55From patient selection to TIL expansion: a comprehensive ove…

… discussing urinary symptoms with patients prior to prescribing SGLT2is. Further research is critically needed to address these issues …